Adagene Inc.
Anti-CD137 molecules and use thereof

Last updated:

Abstract:

The present disclosure provides antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.

Status:
Grant
Type:

Utility

Filling date:

21 Aug 2018

Issue date:

8 Feb 2022